CollPlant (CLGN) receives Nasdaq minimum bid-price notice, given time to cure

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd. received a Nasdaq notice on March 23, 2026 that it is not in compliance with Nasdaq Listing Rule 5550(a)(2) because its ordinary share closing bid price has been below $1.00 per share for the last 30 consecutive business days.

The company has been given a 180-day grace period, until September 21, 2026, to regain compliance by having its closing bid at or above $1.00 for at least 10 consecutive business days. If it still does not meet the minimum bid price by that date, it may qualify for a second 180-day period if it meets other Nasdaq Capital Market initial listing standards and notifies Nasdaq of its intention to cure the deficiency, including potentially effecting a reverse share split. During this time, CollPlant’s ordinary shares remain listed and trading on the Nasdaq Capital Market while the company monitors its share price and evaluates options.

Positive

• None.

Negative

• Nasdaq minimum bid deficiency and delisting risk: CollPlant’s ordinary shares have traded below $1.00 for 30 consecutive business days, triggering a Nasdaq notice and starting a compliance timeline that could lead to delisting if the bid price is not restored.

Insights

Equity markets and listing standards analyst

CollPlant faces Nasdaq bid-price deficiency but retains time to cure.

CollPlant Biotechnologies has fallen out of compliance with Nasdaq’s $1.00 minimum bid price rule after 30 consecutive business days below that level. Nasdaq has granted a 180-day compliance window ending September 21, 2026 to restore the share price above the threshold for 10 consecutive business days.

If compliance is not regained by that date, a second 180-day period is possible, provided the company meets all other Nasdaq Capital Market initial listing criteria and submits an intention to cure, potentially via a reverse share split. The filing states that the shares continue to trade on Nasdaq, so any impact on investors depends on whether the company ultimately avoids delisting.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number 001-38370

CollPlant Biotechnologies Ltd.

(Exact name of registrant as specified in its charter)

4 Oppenheimer St, Weizmann Science Park

Rehovot 7670104, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

This Form 6-K including the press release attached hereto is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-229163, 333-248479, 333-263842, 333-271320 and 333-279791) and Form F-3 (File No. 333-238731 and 333-292640), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On March 24, 2026, CollPlant Biotechnologies Ltd. issued a press release entitled “CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Attached hereto and incorporated by reference herein are the following exhibits:

99.1 Press Release, dated March 24, 2026.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COLLPLANT BIOTECHNOLOGIES LTD.
Date: March 24, 2026	By:	/s/ Eran Rotem
		Name:	Eran Rotem
		Title:	Deputy CEO and Chief Financial Officer

2

Exhibit 99.1

CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement

REHOVOT, Israel, March 24, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced that on March 23, 2026, the Company received a written notice (the “Notice”) from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company’s closing bid price for its ordinary shares, or Ordinary Shares, was below $1.00 per share for the last 30 consecutive business days.

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until September 21, 2026, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Ordinary Shares must meet or exceed $1.00 per share for at least 10 consecutive business days during the 180-calendar day compliance period.

If the Company is not in compliance by September 21, 2026, the Company may be afforded a second 180-calendar day compliance period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse share split, if necessary. If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s Ordinary Shares will be subject to delisting.

The Company intends to monitor the closing bid price of its Ordinary Shares between now and September 21, 2026, and intends to consider available options to cure the deficiency and regain compliance with the minimum bid price requirement within the compliance period. The Company’s Ordinary Shares will continue to be listed and trade on the Nasdaq Capital Market during this period, and are unaffected by the receipt of the written notice from Nasdaq.

This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company’s products are based on its rhCollagen (recombinant human collagen) produced with CollPlant’s proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.

In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. For more information about CollPlant, visit http://www.collplant.com.

Forward-Looking Statements

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant’s objectives, plans and strategies, including statements regarding the Company’s ability to regain compliance with Nasdaq’s minimum bid price requirement, the timing and potential effectiveness of any actions the Company may undertake to cure such deficiency, including the implementation of a reverse share split, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company’s ability to regain compliance with the Nasdaq minimum bid price requirement, the Company’s history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company’s expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics; the Company’s or it strategic partners’ ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based bioink and medical aesthetics products or product candidates including, but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company’s rhCollagen based products, in 3D bioprinting and medical aesthetics; the Company’s ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company’s ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company’s reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company’s ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in Israel, projected capital expenditures and liquidity, changes in the Company’s strategy, and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant are contained under the heading “Risk Factors” included in CollPlant’s most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant’s current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Eran Rotem

Deputy CEO & CFO

Tel: + 972-73-2325600

Email: Eran@CollPlant.com

FAQ

What Nasdaq issue did CollPlant Biotechnologies (CLGN) disclose in this 6-K?

CollPlant disclosed it is not in compliance with Nasdaq Listing Rule 5550(a)(2) because its ordinary share closing bid price stayed below $1.00 for 30 consecutive business days, triggering a formal deficiency notice and a defined compliance timetable.

How long does CollPlant (CLGN) have to regain Nasdaq minimum bid price compliance?

CollPlant has an initial 180-day compliance period, until September 21, 2026, to lift its closing bid price to at least $1.00 for 10 consecutive business days, as required under Nasdaq Listing Rule 5810(c)(3)(A).

Can CollPlant (CLGN) receive additional time from Nasdaq to fix the bid price issue?

Yes. If still non-compliant by September 21, 2026, CollPlant may receive a second 180-day period if it meets all other Nasdaq Capital Market initial listing standards, including market value of publicly held shares, and formally indicates an intention to cure the deficiency.

What actions might CollPlant (CLGN) consider to regain Nasdaq compliance?

The company states it will monitor its share price and consider available options to cure the deficiency. The disclosure notes that regaining compliance during a potential second period may involve a reverse share split, if necessary, subject to meeting Nasdaq conditions.

Will CollPlant’s (CLGN) shares keep trading on Nasdaq during the compliance period?

Yes. CollPlant states its ordinary shares will continue to be listed and trade on the Nasdaq Capital Market while it works to address the minimum bid price deficiency, and the shares are unaffected in the near term by receiving the written Nasdaq notice.

What happens if CollPlant (CLGN) cannot regain Nasdaq minimum bid price compliance?

If CollPlant fails to regain compliance within the allowed 180-day period and any additional 180-day extension, Nasdaq would issue a notice that the company’s ordinary shares are subject to delisting, according to the company’s disclosure.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE, DATED MARCH 24, 2026 12.5 KB